Biological
Cipaglucosidase alfa
Cipaglucosidase alfa is a biological therapy with 4 clinical trials. Currently 3 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
3(75%)
Results Posted
100%(1 trials)
Phase Distribution
Ph phase_3
3
75%
Phase Distribution
0
Early Stage
0
Mid Stage
3
Late Stage
Phase Distribution3 total trials
Phase 3Large-scale testing
3(100.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Completed(1)
Detailed Status
Recruiting2
Active, not recruiting1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
3
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 33 (100.0%)
Trials by Status
active_not_recruiting125%
completed125%
recruiting250%
Recent Activity
3 active trials
Showing 4 of 4
recruiting
A Global Prospective Observational Registry of Patients With Pompe Disease
NCT06121011
recruitingphase_3
A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18
NCT04808505
active_not_recruitingphase_3
ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD
NCT03911505
completedphase_3
A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease
NCT03729362
Clinical Trials (4)
Showing 4 of 4 trials
NCT06121011
A Global Prospective Observational Registry of Patients With Pompe Disease
NCT04808505Phase 3
A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18
NCT03911505Phase 3
ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD
NCT03729362Phase 3
A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease
All 4 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 4